How many Pills? Ask your Genes


In a medical study, the European research project EU-PACT is investigating the link between genetic profiles and anticoagulant dosage, focusing on Anton van den Besselaar’s personalised treatment for blood clotting problems. The seven-country EU-PACT clinical trial is investigating whether the integration of genetic data improves the safety and efficacy of treatment. Early results suggest that tailored doses based on genetic variants could reduce bleeding events. Proponents see potential for widespread genotyping, but others urge caution due to inconclusive evidence and high costs.

The report highlights the potential of genetic testing to transform anticoagulant therapy, and emphasises the importance of continued research and accessibility.

The EU-PACT project was completed in 2013.


By downloading any of the following media, you agree to the Consent to Rights of Use.

Video How many Pills? Ask your Genes

  • 3:20
  • 1920x1080
  • 361.06 MB
  • 25fps, h264, mp4

BRoll footage How many Pills? Ask your Genes

  • 10:20
  • 1920x1080
  • 1126.94 MB
  • 25fps, h264, mp4

Related stories

Welcome back


Consent to rights of use subject to conditions

We grant the following rights of use on the condition that:

The content is used for editorial purposes and not for commercial advertising or any other commercial use.

The following is agreed upon:

  1. we grant journalists, associations, scientists, organisations and other interested parties the non-exclusive right to use the photos, texts and videos (hereinafter referred to as “content”) provided by us and made available here for download for editorial purposes.
  2. The use of the content is permitted in all media, including print publications, online platforms, and social media.
  3. you may edit the content, provided that the edits do not distort the content or take the content out of its context.
  4. Attribution is not required.
  5. Use of the content for purely commercial purposes, such as advertising or promotion, is not permitted without our expressed written consent.
  6. These rights of use commence at the time the content is downloaded and are perpetual.
  7. You may not transfer these rights of use to any third party unless such third party agrees to be bound by the same terms, conditions and restrictions as those set out herein.
  8. These rights of use apply only to the content provided by us and do not extend to any other content or works.

By downloading the content, the user agrees to be bound by the foregoing terms and conditions.

Science Stories offers compelling stories, free video footage, interviews and other content related to European research projects under the Consents to rights of use.

Follow us

Subscribe to our newsletter